



For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure

Tokyo, Japan (February 9, 2016) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced its decision to close its development subsidiary, Daiichi Sankyo Development Limited (based in Gerrards Cross, England; hereafter, DSD). This decision is part of our effort to streamline and enhance the efficiency of our research and development operations that we previously announced on December 1, 2015 in the release entitled, “Daiichi Sankyo Announces Reorganization of its Research & Development Structure.”

DSD presently employs approximately 80 people engaged in the development of pharmaceuticals in Europe. Upon its closure, Daiichi Sankyo will transfer essential development capabilities to its American development subsidiary, Daiichi Sankyo Pharma Development (based in Edison, New Jersey), and to its European subsidiary, Daiichi Sankyo Europe GmbH (based in Munich, Germany).

The financial impact of the closure of DSD on Daiichi Sankyo’s FY2015 business results will be announced at an appropriate time in the future.